RESULTS OF MEDICATION TREATMENT OF SKIN HAEMANGIOMAS AROUND THE EYE IN CHILDREN UNDER 1 YEAR OLD
Keywords:
Hemangioma, children, propranolol, periorbital, USE dopplerography.Abstract
This article describes the course, clinical features, prevalence, modern diagnosis, classification and modern treatment methods of periocular cutaneous hemangioma in children, as well as the results of drug treatment. The study analyzed the results of drug treatment of 34 patients treated on an outpatient basis between 2022 and 2026. The results of treatment were compared, taking into account the period of first referral of children during the breastfeeding period.
Downloads
References
1.Goto, K., Ozeki, M., Yasue, S., Endo, S., & Fukao, T. (2020). Retrospective study of propranolol 2 or 3 mg/kg/day for infantile hemangioma. Pediatrician International, 62(6), 751-753.
2.Karimov M.A, Sadikov R.R, Makhmudova R.Y, Yakubov A.A, Turgunov Z, & Rachimberdieva G.A. (2023). Comparative Effectiveness Of Treatment Of Oral Hemangiomas With Ir-Lasers. Eurasian Scientific Herald, 20, 5–11. Retrieved from https://www.geniusjournals.org/index.php/esh/article/view/4091
3.Karimov M.A. New approaches in the diagnosis of oral hemangiomas American Journal of Medical Sciences and Pharmaceutical Research Doi: https://doi.org/10.37547/TAJMSPR/ Volume02 Issue08 August 20, 2020 | Pages: 50-57
4.Karimov M.A., Kholmirzaev O.N., Inomov Q.S., Karimkulov N.A., Mirzakarimov B.N. (2023). RESULTS OF PROPRONALOL TREATMENT OF FACIAL HEMANGIOMAS. INTERNATIONAL BULLETIN OF MEDICAL SCIENCES AND CLINICAL RESEARCH, 3(9), 5–10. https://doi.org/10.5281/zenodo.8324960
5.Karimov M.A., Sadikov R.R., Karimkulov N.A., Nurmatova X.X. (2023). COMPARATIVE EFFECTIVENESS OF TREATMENT OF ORAL MUCOSAL HEMANGIOMAS WITH IQ-LASERS. INTERNATIONAL BULLETIN OF APPLIED SCIENCE AND TECHNOLOGY, 3(7), 44–49. https://doi.org/10.5281/zenodo.8128871
6.Karimov M.A., Sadikov R.R., Nurmatova Kh.H. (2023). RESULTS OF COMPREHENSIVE TREATMENT OF ORAL HEMANGIOMA. EURASIAN JOURNAL OF ACADEMIC RESEARCH, 3(4), 102–107. https://doi.org/10.5281/zenodo.7805172
7.Leaute-Labrese K, Prey S, Ezzedine K. Infantile hemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J. Eur. acad. Dermatol. Venereol. 2011; 25 (11): 1245–53. doi: 10.1111/j.14683083.2011.04102.x.
8.M. A. Karimov, D. Z. Mamarasulova, R. R. Sadikov, KH. H. Nurmatova RESULT OF TREATMENT OF HEMANGIOMAS OF THE ORAL CAVITY Doctoral Bulletin No. 4 (97)-2020 p. 162-165.
9.M. A., Karimov, Sadikov R. R., and Nurmatova X. X. 2023. “Prevalence and Treatment Results of Oral Hemangiomas in Children”. Middle European Scientific Bulletin 38 (July):70-71. https://cejsr.academicjournal.io/index.php/journal/article/view/1834.
10.M.A.Karimov, R.R.Sadikov, Kh.H.Nurmatova. (2023). OGIZ BOSHLIGI GEMANGIOMALARINI COMPLEX DAVOLASH NATIZHALARI. EURASIAN JOURNAL OF ACADEMIC RESEARCH, 3(4), 102–107. https://doi.org/10.5281/zenodo.7805172
11.M.A.Karimov, R.R.Sadikov, M.M. Mirzaolimov, B.N. Mirzakarimov, X.X.Nurmatova, & G.R. Rakhmonova. (2023). RESULTS OF COMPLEX TREATMENT OF ORAL HEMANGIOMAS. European Scholar Journal, 4(4), 32-35. Retrieved from https://www.scholarzest.com/index.php/esj/article/view/3375
12.Wassef M., Blei F., Adams D., Alomari A., Baselga E., Berenstein A., et al.; ISSVA Board and Scientific Committee. Vascular Anomalies Classification: Recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015; 136(1): e203--14. doi: 10.1542/peds.2014-3673.
13.М.А.Каримов, Р.Р.Садиков, Х.Х.Нурматова. (2023). БОЛАЛАРДА ОҒИЗ БЎШЛИҒИ, БОШ ВА ЮЗ – ЖАҒ СОҲА ГЕМАНГИОМАЛАРИ. YOSH OLIMLAR ILMIY-AMALIY KONFERENSIYASI, 2(03), 90–91. https://doi.org/10.5281/zenodo.7949716
14.М.А.Каримов, Р.Р.Садиков, Х.Х.Нурматова. (2023). ОҒИЗ БЎШЛИҒИ ВА УНИНГ АТРОФИ СОҲА ГЕМАНГИОМАЛАРИ. YOSH OLIMLAR ILMIY-AMALIY KONFERENSIYASI, 2(03), 88–89. https://doi.org/10.5281/zenodo.7949703
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under this license:
- Share: Copy and redistribute the material in any medium or format
- Adapt: Remix, transform, and build upon the material for any purpose, including commercially
Attribution required: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
License URL: https://creativecommons.org/licenses/by/4.0/
Authors retain copyright of their work while granting the journal first publication rights.
